<DOC>
	<DOCNO>NCT02954692</DOCNO>
	<brief_summary>Primary Objective : To assess mean change HbA1c ( glycated haemoglobin ) . Secondary Objectives : To evaluate efficacy safety titration insulin glargine U300 term : - Targeted HbA1c ; - Targeted fasting self- monitoring blood glucose ( SMBG ) ; - Hypoglycemic event ; - Adverse event ; - Quality life assessment DTSQs ( Diabetes Treatment Satisfaction Questionnaire status ) DTSQc ( Diabetes Treatment Satisfaction Questionnaire change ) ; - Blood glucose fluctuation use continuous glucose monitoring system ( CGMS ) subgroup patient .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety Initiation Titration Insulin Glargine ( U300 ) Insulin-naïve Patients With Type 2 Diabetes Mellitus ( T2DM ) Controlled Oral Antidiabetic Drug Treatment Turkey</brief_title>
	<detailed_description>The total study duration per patient 27 week ( 2 week screen , 24 week treatment , 1 week follow-up period ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Meglitinide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Adult patient type 2 diabetes mellitus ( ≥18 year age ) . Type 2 diabetes mellitus diagnosis ≥1 year . Treated ≥1 oral antidiabetic ( ±glucagon like peptid1 ( GLP1 ) analogue ) without insulin , least 6 month HbA1c level 811 % ( insulinnaïve ) . Stable antidiabetic treatment least 3 month . Willingness adherence treatment titration ( include selfinjection , self monitor blood glucose [ SMBG ] ) . Signed informed consent obtain . Exclusion criterion : Age &lt; 18 year old . Type 1 diabetes mellitus . Having secondary type 2 diabetes mellitus . Use insulin therapy include premix , basal plus/basal bolus regimen diagnosis . History hypoglycemia unawareness . Known hypersensitivity/intolerance insulin glargine excipients . Have condition ( include know substance alcohol abuse psychiatric disorder ) preclude patient follow complete study protocol . Use systemic glucocorticoid two week within 12 week prior time screen . Pregnant lactating woman . Participation another clinical trial . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>